arrow
A

Alberto Hernando-Calvo

vall d´hebron hospital campus and institute of oncology
H指数:10
被引数:354

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors

Beamion PANTUMOR-1: Zongertinib二线临床试验的试验依据与设计,用于HER2过表达/扩增或HER2突变的实体瘤

2026-03-040
PRE
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

预测住院癌症患者90天死亡率的预后模型的开发 (PROMISE工具): 一项前瞻性观察研究

2024-11-010
OA
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer
2024-09-012
PRE
Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data
2024-03-010
OAAI
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
MED
IF11.8
2023-10-015
OA
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.

Durvalumab联合奥拉帕利或西地尼布治疗晚期平滑肌肉瘤的安全性、免疫学和临床活性: DAPPER临床试验结果.

2023-08-115
PRE
Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients

复发或转移性头颈部鳞状细胞癌患者的营养状况与免疫治疗临床结局相关

2023-05-018
OAAI
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials
2021-09-011
OA
Molecular enrichment and outcomes based on ESCAT levels in metastatic salivary gland tumours (mSGT) patients (pts) treated in early clinical trials
2020-09-010
OAAI